10-Q: Marker Therapeutics Reports Wider Loss, Going Concern Warning

Marker Therapeutics, a clinical-stage immuno-oncology company, reported a significantly wider net loss for Q2 2025 and issued a going concern warning, despite positive early clinical data for its lead therapy MT-601 and recent capital raises.

Summary

• Net loss for the three months ended June 30, 2025, increased by 83% to $4.02 million, compared to $2.19 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, increased by 85% to $8.46 million, compared to $4.59 million for the same period in 2024.
• Grant income decreased by 26% to $0.86 million for the three months ended June 30, 2025, and by 50% to $1.21 million for the six months ended June 30, 2025, compared to the prior year periods.
• Research and development expenses increased by 79% to $4.18 million for the three months ended June 30, 2025, and by 49% to $7.31 million for the six months ended June 30, 2025, primarily due to increased clinical trial expenses.
• Cash, cash equivalents, and restricted cash stood at $11.8 million as of June 30, 2025, down from $19.2 million at December 31, 2024.
• The company anticipates being able to fund operations into the second quarter of 2026, assuming no additional grant funds are received, which raises substantial doubt about its ability to continue as a going concern.
• Positive early clinical data from the Phase 1 APOLLO study for MT-601 in lymphoma patients showed 78% objective response rate and 44.4% complete response rate in the first dose cohort, with no dose-limiting toxicities or ICANS.
• A Statement of Work was entered into with Cellipont Bioservices on June 16, 2025, for the manufacturing of MT-601 to support the APOLLO study scale-up and cGMP production.
• The Master Services Agreement with Cell Ready was terminated on March 27, 2025, with a settlement payment of approximately $453,000.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a widening net loss, declining grant income, and a 'going concern' warning, indicating high operational risk. While positive early clinical data for MT-601 and new manufacturing partnerships offer some long-term potential, the immediate financial instability and reliance on future capital raises are major concerns.

Positives

• MT-601, a Multi-Antigen Recognizing (MAR)-T cell product candidate, showed promising early objective responses (78%) and complete responses (44.4%) in the Phase 1 APOLLO study for lymphoma patients.
• The MT-601 therapy demonstrated a favorable safety profile, with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS) and only one reported Grade 1 cytokine release syndrome (CRS), indicating low toxicity compared to other cellular therapies.
• The company secured a new Contract Development and Manufacturing Organization (CDMO), Cellipont Bioservices, for MT-601 manufacturing, which is crucial for scaling up production for the pivotal Lymphoma trial in 2026.
• Recent capital raises, including $4.5 million net proceeds from an At The Market (ATM) offering in July 2025 and approximately $14.9 million net proceeds from a private placement in December 2024, have provided additional liquidity.
• Management's proactive approach to addressing liquidity concerns by considering additional capital raises and applying for more grant funds.

Negatives

• The company reported a significant increase in net loss, with a 83% rise for the three months and 85% for the six months ended June 30, 2025, compared to the prior year.
• Grant income, a primary source of revenue, decreased by 26% for the three months and 50% for the six months ended June 30, 2025, indicating reduced non-dilutive funding.
• Cash, cash equivalents, and restricted cash declined from $19.2 million at December 31, 2024, to $11.8 million at June 30, 2025, reflecting a high cash burn rate.
• The company explicitly stated that factors raise substantial doubt regarding its ability to continue as a going concern, highlighting significant financial instability.
• A loss of $453,135 was incurred on the early termination of the vendor agreement with Cell Ready, indicating a disruption in manufacturing strategy and an unexpected expense.

Risks

• Ability to access potential markets for product candidates.
• Ability to secure sufficient future financing to fund operations.
• Successful progression of product candidates through preclinical and clinical development.
• Obtaining regulatory approval for product candidates.
• Maintaining and enforcing intellectual property rights.
• Developing a customer base for commercialized products.
• Attracting, retaining, and motivating qualified personnel.
• Developing strategic alliances and collaborations.
• Assumptions about capital resources may be incorrect, leading to faster depletion of funds.
• Operating plan changes may necessitate additional funds sooner than anticipated.
• Inability to estimate increased capital outlays and operating expenditures for current and anticipated clinical trials.
• No guarantee that third-party manufacturers will perform on proposed timelines or meet manufacturing demands.
• High inflation and economic recession concerns may reduce access to capital and negatively affect liquidity and stock value.
• Future equity or convertible debt financings will dilute existing stockholders' ownership interests.
• Incurrence of indebtedness could result in increased fixed payment obligations and restrictive covenants.
• Strategic partnerships may require relinquishing valuable rights or granting licenses on unfavorable terms.
• Potential damages or liabilities associated with litigation or other legal proceedings.

Future Outlook

The company expects to continue incurring substantial losses as it invests in research and development, including clinical development of its MAR-T cell product candidates. It anticipates being able to fund operations into the second quarter of 2026, assuming no additional grant funds are received. Management is considering raising additional capital through securities issuance and applying for more grant funds to extend its funding beyond Q2 2026. Future funding requirements are highly dependent on the progress of clinical trials, regulatory approvals, manufacturing capabilities, and commercialization efforts.

Management Comments

• "We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our MAR-T cell product candidates."
• "Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of June 30, 2025, and taking into consideration the net proceeds received in July of 2025 through the sale of Common Stock pursuant to its ATM Agreement with H.C. Wainwright & Co., LLC, we anticipate that we will be able to fund our operating expenses and capital expenditure requirements into the second quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding our ability to continue as a going concern."
• "We are considering raising additional capital through the issuance of securities and intend to apply for additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the second quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded."

Industry Context

Marker Therapeutics operates in the highly competitive and capital-intensive immuno-oncology sector, specifically focusing on T-cell based immunotherapies. The shift from Baylor College of Medicine to Cellipont Bioservices for manufacturing reflects a common industry trend for clinical-stage biotechs to scale up production capabilities as they approach pivotal trials and potential commercialization. The positive early clinical data for MT-601, particularly its safety profile compared to CAR-T therapies (no ICANS), positions it as a potentially differentiated product in the crowded T-cell therapy space. However, the significant cash burn and going concern warning are typical challenges for clinical-stage biotechs that have not yet achieved commercial revenue, underscoring the high financial risk inherent in drug development.

Comparison to Industry Standards

• The reported safety profile of MT-601, with no ICANS and only Grade 1 CRS, appears favorable compared to some other T-cell therapies, particularly genetically engineered CAR-T therapies, which have historically been associated with higher rates of severe neurotoxicity and cytokine release syndrome. For example, approved CAR-T therapies like Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) have reported higher incidences of Grade 3 or higher CRS and neurotoxicity.
• The objective response rate of 78% and complete response rate of 44.4% in the first dose cohort of the APOLLO study for lymphoma patients are encouraging for an early-stage trial. While direct comparisons are difficult without full trial details, these rates are competitive with early-phase data from other novel T-cell therapies targeting hematological malignancies.
• The company's reliance on grant funding and equity raises, coupled with a 'going concern' warning, is a common characteristic of clinical-stage biotechnology companies that are pre-revenue. Many peers in this stage, such as smaller biotechs developing cell therapies, face similar liquidity challenges and frequently engage in ATM offerings, private placements, or other dilutive financing activities to sustain operations and advance their pipelines.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that are believed to have a material adverse effect on the business, operating results, or financial condition.

Related Party Transactions

• Baylor College of Medicine (BCM): Incurred $1.9 million (three months) and $2.5 million (six months) in expenses for services and manufacturing costs during Q2 2025. Paid BCM approximately $1.8 million (three months) and $1.9 million (six months) for invoices received. BCM is also a shareholder and licensor of the company's core technology.
• Wilson Wolf Manufacturing Corporation: Incurred approximately $21,000 (three months) and $50,000 (six months) in expenses for cell culture devices during Q2 2025. Paid Wilson Wolf approximately nil (three months) and $95,000 (six months) for invoices received. Mr. John Wilson, a former director, is CEO of Wilson Wolf.
• Cell Ready, LLC: Incurred nil (three months) and $0.6 million (six months) in expenses for services and manufacturing costs during Q2 2025. Paid nil (three months) and $2.6 million (six months) for invoices received. The Master Services Agreement was terminated on March 27, 2025, with a settlement payment of approximately $453,000. Cell Ready is owned by former director Mr. John Wilson.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and potential future equity raises (ATM, private placements) due to the company's substantial capital needs and going concern warning. The increased net loss and declining cash position could negatively impact share price.
• Employees: The company's financial instability and going concern warning could create uncertainty regarding job security, although increased R&D spend suggests continued investment in personnel for clinical development.
• Customers (future): Potential patients could benefit from the promising early clinical data of MT-601, but the company's financial viability is critical for continued product development and eventual commercialization.
• Suppliers/Creditors: The going concern warning and reliance on future capital raises introduce risk for suppliers and creditors, potentially affecting payment terms or willingness to extend credit.
• Grant Providers (CPRIT, FDA, NIH SBIR): Continue to provide significant funding, but the company's ability to meet grant terms and achieve milestones is crucial for continued support. Revenue-sharing arrangements with CPRIT indicate a long-term financial commitment if products are commercialized.

Next Steps

• Continue clinical investigation of MT-401 as an Off-the-Shelf (OTS) product in patients with Acute Myeloid Leukemia (AML) under the CPRIT AML Grant.
• Continue clinical investigation of MT-401 for the treatment of post-transplant AML under the FDA Grant.
• Continue development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents under the SBIR AML Grant.
• Continue support for control over tumor immune escape in pancreatic cancer using a dual T cell product strategy under the Decoy Grant.
• Continue clinical investigation of MT-601 in patients with non-Hodgkins lymphoma (NHL) who have relapsed following anti-CD19 CAR-T cell therapy.
• Continue advancement of MT-601 in patients with pancreatic cancer under the PANACEA Grant.
• Continue clinical investigation of MT-601 in patients with metastatic pancreatic cancer under the CPRIT Pancreatic Grant.
• Cellipont Bioservices to provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for the APOLLO study.
• Commencement of the larger pivotal trial for Lymphoma anticipated in 2026.
• Management is considering raising additional capital through the issuance of securities and intends to apply for additional grant funds.
• Assess the impact of ASU 2024-03 on disclosures, effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027.

Key Dates

Recommendation

The company's financial position is highly precarious, evidenced by a substantial increase in net losses, declining grant income, and an explicit 'going concern' warning. While positive early clinical data for MT-601 is encouraging, the significant cash burn and the need for continuous capital raises (which will lead to further shareholder dilution) present an extremely high-risk investment profile. The company's ability to fund operations is projected only into Q2 2026 without additional funding, making it a speculative investment with considerable downside risk. A seasoned investor would likely avoid or exit this position given the severe liquidity concerns and the uncertainty surrounding future funding.

Keywords

Immuno-oncology, T-cell therapy, MAR-T cell, MT-601, MT-401-OTS, Lymphoma, Pancreatic cancer, Acute Myeloid Leukemia, AML, Clinical-stage, Biotechnology, SEC filing, 10-Q, Going concern, Clinical trials, Cell therapy manufacturing, Oncology